Resultados de un servicio internacional de análisis de sustancias para usuarios de mercados encriptados
La mayoría de las sustancias analizadas contenían el ingrediente anunciado y eran de alta pureza. Más información, en inglés, está disponible abajo.
Suscríbase a las Alertas mensuales del IDPC para recibir información sobre cuestiones relacionadas con políticas sobre drogas.
By Fernando Caudevilla, Mireia Ventura, Iván Fornís, Monica J. Barratt, Claudio Vidal, Cristina Gil lladanosa, Pol Quintana, Ana Muñoz, Nuria Calzada.
Introduction
User surveys indicate that expectations of higher drug purity are a key reason for cryptomarket use. In 2014–2015, Spain's NGO Energy Control conducted a 1-year pilot project to provide a testing service to cryptomarket drug users using the Transnational European Drug Information (TEDI) guidelines. In this paper, we present content and purity data from the trial.
Methods
219 samples were analyzed by gas chromatography associated with mass spectrometry (GC/MS). Users were asked to report what substance they allegedly purchased.
Results
40 different advertised substances were reported, although 77.6% were common recreational drugs (cocaine, MDMA, amphetamines, LSD, ketamine, cannabis). In 200 samples (91.3%), the main result of analysis matched the advertised substance. Where the advertised compound was detected, purity levels (m ± SD) were: cocaine 71.6 ± 19.4%; MDMA (crystal) 88.3 ± 1.4%; MDMA (pills) 133.3 ± 38.4 mg; Amphetamine (speed) 51.3 ± 33.9%; LSD 123.6 ± 40.5 μg; Cannabis resin THC: 16.5 ± 7.5% CBD: 3.4 ± 1.5%; Ketamine 71.3 ± 38.4%. 39.8% of cocaine samples contained the adulterant levamisole (11.6 ± 8%). No adulterants were found in MDMA and LSD samples.
Discussion
The largest collection of test results from drug samples delivered from cryptomarkets are reported in this study. Most substances contained the advertised ingredient and most samples were of high purity. The representativeness of these results is unknown.
Click here to read the full article.
Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.
Thumbnail: Flickr CC Wikipedia Commons